CA3176944A1 - 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer - Google Patents
5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancerInfo
- Publication number
- CA3176944A1 CA3176944A1 CA3176944A CA3176944A CA3176944A1 CA 3176944 A1 CA3176944 A1 CA 3176944A1 CA 3176944 A CA3176944 A CA 3176944A CA 3176944 A CA3176944 A CA 3176944A CA 3176944 A1 CA3176944 A1 CA 3176944A1
- Authority
- CA
- Canada
- Prior art keywords
- amino
- pyrimidin
- triazolo
- pyridy1
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062994908P | 2020-03-26 | 2020-03-26 | |
| US62/994,908 | 2020-03-26 | ||
| PCT/EP2021/057806 WO2021191378A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3176944A1 true CA3176944A1 (en) | 2021-09-30 |
Family
ID=75339740
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3176944A Pending CA3176944A1 (en) | 2020-03-26 | 2021-03-25 | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20230271964A1 (https=) |
| EP (1) | EP4126872A1 (https=) |
| JP (1) | JP7675094B2 (https=) |
| KR (1) | KR20230049579A (https=) |
| CN (1) | CN115867282B (https=) |
| AU (1) | AU2021240344A1 (https=) |
| CA (1) | CA3176944A1 (https=) |
| WO (1) | WO2021191378A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3243621A1 (en) * | 2022-02-01 | 2023-08-10 | Eli Lilly And Company | METHODS FOR PREPARING SELECTIVE ESTROGEN RECEPTOR DEGRADING AGENTS |
| JP2025512384A (ja) | 2022-04-13 | 2025-04-17 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔｒｏｐ－２発現がんを治療するための併用療法 |
| WO2025137640A1 (en) | 2023-12-22 | 2025-06-26 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7452892B2 (en) | 2005-06-17 | 2008-11-18 | Bristol-Myers Squibb Company | Triazolopyrimidine cannabinoid receptor 1 antagonists |
| ATE457988T1 (de) | 2006-06-26 | 2010-03-15 | Schering Corp | A2a-adenosin-rezeptor-antagonisten |
| JP2011513417A (ja) | 2008-03-04 | 2011-04-28 | シェーリング コーポレイション | アデノシンＡ２ａ受容体アンタゴニストとして使用するための１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オンおよびピラゾロ［４，３−ｅ］−１，２，４−トリアゾロ［４，３−ｃ］ピリミジン−３−オン化合物 |
| AU2011306358B2 (en) | 2010-09-24 | 2014-08-14 | Impetis Biosciences Ltd. | Fused tricyclic compounds as adenosine receptor antagonist |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| AU2018233367B2 (en) | 2017-03-16 | 2021-08-12 | Jiangsu Hengrui Medicine Co., Ltd. | Heteroaryl[4,3-c]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof |
-
2021
- 2021-03-25 WO PCT/EP2021/057806 patent/WO2021191378A1/en not_active Ceased
- 2021-03-25 CA CA3176944A patent/CA3176944A1/en active Pending
- 2021-03-25 CN CN202180038001.3A patent/CN115867282B/zh active Active
- 2021-03-25 AU AU2021240344A patent/AU2021240344A1/en active Pending
- 2021-03-25 EP EP21715861.7A patent/EP4126872A1/en active Pending
- 2021-03-25 JP JP2022558347A patent/JP7675094B2/ja active Active
- 2021-03-25 US US17/914,245 patent/US20230271964A1/en active Pending
- 2021-03-25 KR KR1020227037221A patent/KR20230049579A/ko active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4126872A1 (en) | 2023-02-08 |
| US20230271964A1 (en) | 2023-08-31 |
| CN115867282B (zh) | 2025-05-27 |
| KR20230049579A (ko) | 2023-04-13 |
| CN115867282A (zh) | 2023-03-28 |
| WO2021191378A1 (en) | 2021-09-30 |
| JP2023519362A (ja) | 2023-05-10 |
| JP7675094B2 (ja) | 2025-05-12 |
| AU2021240344A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019267008B2 (en) | Tetracyclic heteroaryl compounds | |
| AU2021411587B2 (en) | Indazole compounds as kinase inhibitors | |
| US10005774B2 (en) | Syk inhibitors | |
| KR101862493B1 (ko) | Fgfr4 억제제로서의 고리-융합된 비시클릭 피리딜 유도체 | |
| AU2022232523A1 (en) | Kras g12d inhibitors | |
| CA3217856A1 (en) | Heterocyclic compounds and methods of use | |
| AU2021401232A1 (en) | Azaquinazoline pan-kras inhibitors | |
| CA3176944A1 (en) | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | |
| KR20230049580A (ko) | 트리아졸론 화합물 | |
| WO2021191379A1 (en) | 5-amino-8-(4-pyridyl)-[1,2,4]triazolo[4,3-c]pyrimidin-3-one compounds for use against cancer | |
| KR20250008781A (ko) | NF-κB 유도 키나제의 억제제로서의 피롤리디논 유도체 | |
| TW202504586A (zh) | 治療發炎性疾病之方法 | |
| HK1224672A1 (en) | Syk inhibitors | |
| HK1224672B (en) | Syk inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20240705 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241023 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241223 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250102 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250102 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20250317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250317 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250324 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20250429 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250512 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20260303 |